Tarsus Pharmaceuticals, Inc. (TARS) · Aug 6, 2026 · Company update

XDEMVY sales beat expectations, but heavier spending drove a sharp EPS miss

XDEMVY sales beat expectations, but heavier spending drove a sharp EPS miss

Sales came in ahead of the market’s bar. Q2 total revenue was $173.9 million versus published consensus of roughly $167.3 million, with product sales accounting for the entire quarter (Financial Highlights). XDEMVY sales therefore grew about 69% year over year, a solid commercial result against expectations.

$ millions, except EPSQ2 2026Q2 2025Published expectation
Product sales, net173.9102.7—
Total revenues173.9102.7~167.3
Gross margin93%94%—
Net loss(18.6)(20.3)—
Net loss per share(0.43)(0.48)roughly (0.22)

The earnings conversion was materially worse than the sales headline suggests. GAAP loss per share was $0.43 versus a published expectation near $0.22 loss, as SG&A rose to $150.7 million from $103.0 million and R&D increased to $31.0 million from $15.6 million (Income Statement; SG&A expenses; R&D expenses). Commercial advertising, patient support, personnel, and pipeline spending absorbed most of the revenue upside, leaving the operating loss at $19.9 million despite the strong sales growth.

The underlying margin profile held, but profitability remains intentionally deferred. Gross margin was 93%, only modestly below 94% a year earlier (Cost of sales). The improvement in net loss versus $20.3 million last year was helped by $2.8 million of investment-exchange gains and $16.7 million of first-half China milestone revenue; neither meaningfully changes the recurring commercial profitability picture (Other income; License fees and collaboration revenue).

Pipeline expansion is strategically meaningful but adds execution and capital demands. Tarsus completed the iRenix acquisition and agreed to acquire Alkeus, adding a late-stage retina asset and a Phase 3 Stargardt program, while Calliope enrollment was completed and KORE continued toward first-half 2027 data (Recent business achievements). The filing does not provide the Alkeus transaction value or quantify its expected near-term financial impact, so the deal broadens the opportunity set but cannot yet be judged financially against consensus.

Net read: strong demand, offset by a clear earnings miss and higher investment intensity. First-half product sales reached $319.3 million, putting the business on track operationally against the previously stated $670–700 million 2026 XDEMVY sales range, but the filing excerpt does not state the updated annual guidance range, so any raise or cut cannot be assessed precisely (Financial Highlights; prior company guidance). The quarter is therefore better on revenue than expected, worse on per-share earnings, and broadly mixed overall rather than a clean beat.

Original filing on SEC EDGAR

More Tarsus Pharmaceuticals, Inc. news

XDEMVY sales beat expectations, but heavier spending drove a sharp EPS miss | TARS Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.